Q1 2025 Earnings Call Transcript April 29, 2025 Regeneron Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS ...

Shares of Regeneron Pharmaceuticals are trading higher Wednesday recovering after a drop on Tuesday that followed the release ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

"We have made meaningful progress across our pipeline so far in ... an sBLA to the FDA and a regulatory application in the EU for Libtayo (cemiplimab) in adjuvant CSCC based upon data from a ...

First quarter 2025 revenues of $3.0 billion; GAAP diluted EPS of $7.27 and non-GAAP diluted EPS(a) of $8.22First quarter 2025 Dupixent® global net sales (recorded by Sanofi) increased 19% to $3.67 bil ...

We are also working to ensure our four blockbuster medicines reach even more patients who could benefit, with year-to-date progress including ... in the EU for Libtayo (cemiplimab) in adjuvant ...

Key topics include results from the Phase 3 trial of Libtayo for high-risk cutaneous ... like linvoseltamab and odronextamab is still in progress, highlighting uncertainty in their future success ...

“With regard to the more personal Siri features we announced, we need more time to complete our work on these features so they meet our high-quality bar. We are making progress, and we look ...